COGT - Cogent Biosciences, Inc.
IEX Last Trade
7.7
-0.080 -1.039%
Share volume: 6,131
Last Updated: Thu 26 Dec 2024 04:30:00 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
4.47%
PREVIOUS CLOSE
CHG
CHG%
$7.78
-0.08
-1.03%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
0.26%
1 Month
-14.47%
3 Months
-27.76%
6 Months
-5.53%
1 Year
36.93%
2 Year
-28.48%
Key data
Stock price
$7.70
DAY RANGE
$7.67 - $7.87
52 WEEK RANGE
$4.50 - $12.61
52 WEEK CHANGE
$33.90
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
10/31/2024
Company detail
CEO: Andrew R. Robbins
Region: US
Website: cogentbio.com
Employees: 80
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: cogentbio.com
Employees: 80
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Cogent Biosciences, Inc. focuses on developing precision therapies for genetically defined diseases. Lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis.
Recent news